Rotorless vulcanizer document.write('') First, characteristics and uses: document.write ('') rotorless vulcanizer document.write ('') in line with GB/T 16584 "Rubber without rotor vulcanization test for determination of vulcanization characteristics", ISO 6502 requirements and Italian standards T30 , T60, T90 data. The rotorless vulcanizer is used to determine the characteristics of unvulcanized rubber and to find out the suitable cure time for the rubber. It adopts imported intelligent digital temperature control instrument, which is easy to adjust and set, wide temperature control range and high control precision. Its stability, importance and accuracy are better than those of general rotary vulcanizer. The microcomputer adopts imported chips, which has high reliability, and all data can be automatically drawn, calculated and printed. With copy and enlargement. Ziprasidone Intermediates
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.
Ziprasidone Intermediates Ziprasidone Intermediates,Cas 7716-66-7 ,Cas 2634-33-5,Ziprasidone Hydrochloride Intermediate Nanjing Sunshine Biotech Co., Ltd , https://www.sunshine-bio.com
Second, technical parameters
1, temperature range: room temperature ~ 200 ° C
2. Temperature fluctuation: ±0.1
3, temperature display resolution: 0.1 ° C
4, heating rate: at room temperature -200 ° C, about 10min to reach equilibrium
5. Torque range: 0N.m-5N.m
6, time setting range: 2min ~ 120min optional
7, the rotor swing angle: 0.5 ° (total amplitude is 1 °)
8, rotor swing frequency: 1.7Hz ± 0.1Hz (100r / min)
9, power consumption: 800W
10, power supply: AC220V 50Hz
11, dimensions: 645mm × 580mm × 1300mm
12, net weight: 210kg 
Ziprasidone is a medication of the atypical antipsychotic type. It is used for the treatment of schizophrenia as well as acute mania and mixed states associated with bipolar disorder. Its intramuscular injection form is approved for acute agitation in people with schizophrenia. Ziprasidone is also used off-label for depression, bipolar maintenance, and posttraumatic stress disorder.
Ziprazidone is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia as well as acute mania and mixed states associated with bipolar disorder. Its intramuscular injection form is approved for acute agitation in schizophrenic patients for whom treatment with just ziprasidone is appropriate.
We produce a series of complete intermediates for Ziprasidone, intermediate I (CAS No. 2634-33-5) and intermediate II (CAS No. 7716-66-7) etc.
